NASDAQ$STAA

STAAR Surgical Company · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

STAAR Surgical's Q1 2024 results reflected the impact of commercial focus, driving market adoption and share gains of EVO ICL, with strategic investments bearing fruit and momentum quickening, marked by significant business milestones.

STAAR Surgical reported a 5% increase in net sales to $77.4 million in Q1 2024, with ICL sales up by 9%. The company experienced a net loss of $3.3 million, or $0.07 per share, compared to a net income of $2.7 million, or $0.05 per share in the prior year quarter. The company reiterated its fiscal year 2024 net sales outlook of $335 million to $340 million and increased Adjusted EBITDA outlook to approximately $39 million.

  • Net sales increased by 5% to $77.4 million, and 7% in constant currency.
  • ICL sales increased by 9%, with unit growth of 2%.
  • Gross margin was 78.9% compared to 78.3% in the prior year.
  • Cash, cash equivalents, and investments available for sale reached a record $252.1 million.

Headline financials

Total Revenue

$77.4M

Previous: $73.5M+5.2%
EPS

-$0.07

Previous: $0.18-138.9%
Gross Margin

78.9%

No prior period
Adjusted EBITDA

$5.3M

No prior period
Adjusted EBITDA per Share

$0.11

No prior period
Global Sales Growth

5.0%

No prior period
Capital Expenditures

-$5.2M

Previous: -$2.9M-79.3%
Free Cash Flow

-$8.54M

Previous: -$191K-4371.7%
Net Income

-$3.34M

Previous: $2.71M-223.2%
Operating Income

-$2.28M

Previous: $2.8M-181.5%
Gross Profit

$61M

Previous: $57.6M+6.0%
Cash & Equivalents

$224M

Previous: $90M+149.0%
Total Assets

$493M

Previous: $419M+17.6%
R&D Expense

$13.4M

No prior period
Stock-Based Comp

$6.34M

Previous: $6.07M+4.5%

Revenue & EPS history

STAAR Surgical · Revenue · Quarterly

$77.4M

Q1 2024+5.2%vs Q1 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

The Company reiterated its prior outlook for fiscal year 2024 net sales and increased its outlook for Adjusted EBITDA. The Company now expects net sales of $335 million to $340 million and Adjusted EBITDA of approximately $39 million and Adjusted EBITDA per diluted share of approximately $0.75.

Tailwinds

  • Net sales of $335 million to $340 million.
  • Adjusted EBITDA of approximately $39 million.
  • Adjusted EBITDA per diluted share of approximately $0.75.
  • EVO ICL sales growth of approximately 7% in APAC, including 10% in China.
  • 10% growth in the Americas, including 10% in the U.S.

Headwinds

  • EMEA sales consistent with fiscal year 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+2.4%

Avg return

Earnings day

+1.9%

Avg return

5 days after

+3.5%

Avg return

30 days after

50%

30 / 60 earnings

Positive

+29.0%

Q1 2018

Best reaction

-24.7%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.3%+14.5%+0.6%
Q4 2025-1.4%-3.2%+6.8%
Q3 2025-0.3%-4.9%-0.2%
Q1 2025+0.2%-2.3%-8.1%
Q4 2024-24.7%-29.8%-22.1%
Q3 2024-4.3%-3.8%-3.9%
Q2 2024+6.5%+1.7%-17.9%
Q1 2024-10.8%-7.9%-12.0%
Q4 2023+6.6%+8.6%+22.9%
Q3 2023-13.9%-17.5%-21.1%
Q2 2023-10.5%-11.6%-18.4%
Q1 2023-5.8%-1.5%-15.9%
Q4 2022-12.7%-18.4%-9.6%
Q3 2022-18.9%-20.0%-14.1%
Q2 2022+23.1%+26.6%+16.8%
Q1 2022+1.9%-9.3%+7.6%
Q4 2021+13.1%+20.4%+10.7%
Q3 2021-1.5%-1.3%-24.8%
Q2 2021+21.3%+19.4%+22.4%
Q1 2021+8.6%-8.6%+12.6%
Q4 2020-4.3%-4.1%-9.7%
Q3 2020+2.4%+14.8%+7.0%
Q2 2020-6.8%-14.2%-16.7%
Q1 2020-0.5%+3.8%+14.8%
Q4 2019+2.0%+4.1%+1.9%
Q3 2019+14.6%+22.1%+28.8%
Q2 2019+14.9%+5.9%-0.6%
Q1 2019-13.3%-16.8%-28.7%
Q4 2018-0.6%-1.2%+2.7%
Q3 2018+10.6%+13.9%-1.2%
Q2 2018+25.6%+29.3%+54.6%
Q1 2018+29.0%+38.1%+84.8%
Q4 2017-9.1%-8.2%-7.2%
Q3 2017+12.0%+10.5%+17.0%
Q2 2017-1.4%-3.3%+11.6%
Q1 2017-2.9%-3.3%-10.0%
Q4 2016+1.5%-2.4%-4.4%
Q3 2016+9.8%+11.6%+28.0%
Q2 2016+19.9%+21.5%+30.4%
Q1 2016-22.4%
Q4 2015+17.1%
Q3 2015+13.0%
Q2 2015+1.2%
Q1 2015-6.0%
Q4 2013+10.1%
Q3 2013-3.6%
Q2 2013+18.6%
Q1 2013+20.8%
Q4 2012-5.6%
Q3 2012+7.5%
Q2 2012+26.3%
Q1 2011-10.1%
Q1 2012-0.7%
Q4 2011-0.8%
Q1 2009-0.8%
Q3 2010+7.7%
Q3 2011+7.7%
Q4 2010-6.7%
Q2 2010-6.7%
Q2 2011-6.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro